Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 6/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069697 | 0.87 | RET (0.43) | RETSLC22A1SLC6A4ADRA1AOPRM1 | |
| SCHEMBL20147481 | 0.87 | RET (0.36) | RETCHRM3EPHX1EPHX2 | |
| SCHEMBL20147972 | 0.85 | RET (0.35) | RETCHRM3EPHX1EPHX2 | |
| SCHEMBL20069705 | 0.84 | RET (0.41) | RETEPHX1EPHX2SLC22A1SLC6A4 | |
| SCHEMBL20069702 | 0.82 | RET (0.35) | RETCHRM3SLC22A1SLC6A4ADRA1A | |
| SCHEMBL20069706 | 0.81 | EPHX1 (0.50) | RETEPHX1EPHX2 | |
| SCHEMBL20069722 | 0.81 | RET (0.43) | RETCHRM3HDAC3HDAC1HDAC2 | |
| SCHEMBL20158493 | 0.80 | RET (0.44) | RET | |
| SCHEMBL20069700 | 0.80 | CACNA1H (0.37) | RET | |
| SCHEMBL20206011 | 0.78 | RET (0.41) | RETCHRM3EPHX1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| WO-2018071454-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885CHRM3 2379/4885EPHX1 1481/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885CHRM3 2379/4885EPHX1 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.